Loading
Donanemab / Alzheimer Disease · Phase 3 Trial
ClinicalTrials.gov · August 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active Phase 3 registry record for a randomized trial of intravenous donanemab versus placebo in Chinese participants with preclinical Alzheimer's disease. No efficacy or safety results are reported in this registry entry; the trial is recruiting and remains ongoing with an estimated completion window of 156 weeks from baseline.
Phase 3, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Alzheimer Disease; age from 55 Years; to 80 Years. Intervention: Donanemab. Compared with: Placebo — Placebo Comparator. n = 140. 30 sites: China.
This is an active Phase 3 registry record for a randomized trial of intravenous donanemab versus placebo in Chinese participants with preclinical Alzheimer's disease. No efficacy or safety results are reported in this registry entry; the trial is recruiting and remains ongoing with an estimated completion window of 156 weeks from baseline.
No efficacy or safety results are reported in this registry record.
Completion of this trial will provide Phase 3 evidence for donanemab's safety and efficacy in slowing cognitive progression in a Chinese preclinical AD cohort, with potential implications for early intervention in this population. Until results are reported, clinicians cannot assess this agent's clinical utility in this setting.
This is an active Phase 3 trial registration with no results reported; donanemab's efficacy and safety in Chinese preclinical AD remain unevaluated pending completion.
As stated by the source record.
Quoted from the source exactly as published.
Completion of this trial will provide Phase 3 evidence for donanemab's safety and efficacy in slowing cognitive progression in a Chinese preclinical AD cohort, with potential implications for early intervention in this population. Until results are reported, clinicians cannot assess this agent's clinical utility in this setting.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07571161). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 140 participants (ESTIMATED). Conditions: Alzheimer Disease. Interventions: DRUG: Donanemab; DRUG: Placebo. Primary outcome measures: Time to Clinical Progression as Measured by Clinical Dementia Rating-Global Score (CDR-GS) , Baseline Up to Week 156. Brief summary: The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.